open access
Acneiforme eruption in a patient treated with cetuximab due to colon carcinoma
Affiliations- Zakład i Klinika Dermatologii, Szopena 2, 35-055 Rzeszów, Poland
open access
Abstract
Drugs used in the treatment of malignancies may cause various skin eruptions. One of the newer anticancer drugs which may induced cutaneous side effects are epidermal growth factor receptor inhibitors. Here, we demonstrate a 50-year-old man with a cancer of the recto-sigmoid flexion who developed acneiforme drug eruption on the face, scalp, back and chest after the administration of cetuximab. The treatment with oral doxycycline combined with topical corticosteroid was initiated, which resulted in the significant improvement of skin lesions. The anticancer therapy remained unchanged.
Abstract
Drugs used in the treatment of malignancies may cause various skin eruptions. One of the newer anticancer drugs which may induced cutaneous side effects are epidermal growth factor receptor inhibitors. Here, we demonstrate a 50-year-old man with a cancer of the recto-sigmoid flexion who developed acneiforme drug eruption on the face, scalp, back and chest after the administration of cetuximab. The treatment with oral doxycycline combined with topical corticosteroid was initiated, which resulted in the significant improvement of skin lesions. The anticancer therapy remained unchanged.
Keywords
cetuximab, inhibitors of epidermal growth factor receptor, malignancies, drug-induced rash
About this articleTitle
Acneiforme eruption in a patient treated with cetuximab due to colon carcinoma
Journal
Issue
Article type
Case report
Pages
78-80
Published online
2018-08-17
Page views
468
Article views/downloads
1832
Bibliographic record
Forum Dermatologicum 2018;4(2):78-80.
Keywords
cetuximab
inhibitors of epidermal growth factor receptor
malignancies
drug-induced rash
Authors
Kamila Jaworecka
Dominik Samotij
Adam Reich
References (7)- Kowalska M, Kowalik A, Góźdź S. Dermatologiczne objawy uboczne w przebiegu chemioterapii i celowanej terapii przeciwnowotworowej. Przegl Dermatol. 2016; 103: 127–138.
- Belum VR, Marchetti MA, Dusza SW, et al. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. J Am Acad Dermatol. 2017; 77(3): 577–579.
- Vaccaro M, Guarneri F, Borgia F, et al. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. J Dermatolog Treat. 2016; 27(2): 148–152.
- Kryński J, Kamińska-Winciorek G. Leczenie reakcji skórnych występujących podczas terapii inhibitorami receptora nabłonkowego czynnika wzrostu u pacjentów z rakiem jelita grubego. Onkol Prakt Klin. 2010; 6: 318–332.
- Choi JW, Kim TIn, Jeong KH, et al. A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser. Dermatol Ther. 2016; 29(4): 252–254.
- Hofheinz RD, Deplanque G, Komatsu Y, et al. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016; 21(12): 1483–1491.
- Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004; 151(1): 238–241.
